Cytel Expands Access to Powerful Computational Solara Software, Will Reduce Clinical Trial Costs

Cytel decision-making software Solara has been opened for general release. It comes in two setups: one for companies with an in-house biostatistician secondly as part of a consultancy program aimed at small biotechs or pharmaceutical companies lacking a biostatistician. The powerful software tool will significantly reduce costs when it comes to designing clinical trials.

Cytel CEO Joshua Schultz remarks, “A Phase III clinical trial can easily cost $100 million,” adding “Choosing the wrong design not only wastes time and money, but it can also easily prevent safe and effective drugs from reaching the patients who need them.” Read more here.

(Source: Cytel, 3/29/21)